Latest News

Alphabet Seeks More Investors in 20-for-1 Stock Split


(Bloomberg) — Alphabet Inc. announced a 20-for-1 stock split in the form of a one-time special stock dividend, aiming to draw a wider audience for its shares.

Most Read from Bloomberg

Teen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire Jets

Covid-Infected HIV Patient Developed Mutations, Study Shows

SeaWorld Makes $3.4 Billion Takeover Bid for Cedar Fair

U.S. Stocks Post Best Three-Day Rally Since 2020: Markets Wrap

Be Warned — the Turbulence This Time Is Different

“The reason for the split is it makes our shares more accessible,” Ruth Porat, Alphabet’s chief financial officer, said in a conference call with television anchors. “We thought it made sense to do.”

The new class of retail investors often weigh affordability and brand recognition when deciding which stocks to buy. Alphabet has been at a disadvantage, as its stock is expensive and uses the name of a holding company, rather than the globally recognized brand, Google.

The stock split could lead to Alphabet’s listing on the Dow Jones Industrial Average, one of the most commonly quoted indexes that holds 30 blue-chip companies. It could also help the company on its path to cross a $2 trillion market cap. A prior stock split happened in 2014, after the company’s shares topped $1,000.

Porat said the split announced on Tuesday will come at the close of business July 15.

Alphabet shares extended gains to 7% at 4:24 p.m. New York time after the stock split was announced.

For more on Alphabet fourth-quarter earnings, click here for our TOPLive blog.

(Removes erroneous reference to shares split value from fourth paragraph)

Most Read from Bloomberg Businessweek

Rent Inflation Shows That Landlords Have the Upper Hand Again

China’s Local Governments Are at Risk of a Puerto Rico Moment

China’s American-Born Olympic Star Is Being Very Careful

Pharmacy Workers Are the Pandemic’s Invisible Victims

What Happens When Russian Hackers Come for the Electrical Grid

©2022 Bloomberg L.P.

After Alzheimer’s drug flop, Peninsula biotech’s founding execs exit

Previous article

Alphabet Stock Split Could Permit Tech Giant to Join Dow Industrials

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News